Literature DB >> 35020061

Validation of the STARZ neonatal acute kidney injury risk stratification score.

Sidharth Kumar Sethi1, Rupesh Raina2, Abhyuday Rana3, Gopal Agrawal4, Abhishek Tibrewal5, Naveen Bajaj6, Naveen Parkash Gupta7, Shishir Mirgunde8, Jagdish Sahoo9, Binesh Balachandran10, Kamran Afzal11, Anubha Shrivastava12, Jyoti Bagla13, Sushma Krishnegowda14, Ananth Konapur15, Kritika Soni1, Divya Sharma16, Amrit Khooblall17, Prajit Khooblall16, Timothy Bunchman18, Sanjay Wazir4.   

Abstract

BACKGROUND: Neonatal acute kidney injury (AKI) is common in neonatal intensive care units (NICU) and leads to worse outcomes. Stratifying neonates into an "at risk" category allows health care providers to objectively recognize opportunities for improvements in quality of care.
METHODS: The "Neonatal AKI Risk Prediction Scoring" was devised as the "STARZ [Sethi, Tibrewal, Agrawal, Raina, waZir]" Score. The STARZ score was derived from our prior multicentre study analysing risk factors for AKI in neonates admitted to the NICU. This tool includes 10 variables with a total score ranging from 0 to 100 and a cut-off score of 31.5. In the present study, the scoring model has been validated in our multicentre cohort of 744 neonates.
RESULTS: In the validation cohort, this scoring model had sensitivity of 82.1%, specificity 91.7%, positive predictive value 81.2%, negative predictive value 92.2% and accuracy 88.8%. Based on the STARZ cut-off score of ≥ 31.5, an area under the receiver operating characteristic (ROC) curve was observed to be 0.932 (95% CI, 0.910-0.954; p < 0.001) signifying that the discriminative power was high. In the validation cohort, the probability of AKI was less than 20% for scores up to 32, 20-40% for scores between 33 and 36, 40-60% for scores between 37 and 43, 60-80% for scores between 44 and 49, and ≥ 80% for scores ≥ 50.
CONCLUSIONS: To promote the survival of susceptible neonates, early detection and prompt interventional measures based on highly evidenced research is vital. The risk of AKI in admitted neonates can be quantitatively determined by the rapid STARZ scoring system. A higher resolution version of the Graphical abstract is available as Supplementary information.
© 2022. The Author(s), under exclusive licence to International Pediatric Nephrology Association.

Entities:  

Keywords:  Acute kidney injury; Neonatal acute kidney injury; STARZ score

Mesh:

Year:  2022        PMID: 35020061     DOI: 10.1007/s00467-021-05369-1

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.651


  2 in total

1.  Transport Risk Index of Physiologic Stability, version II (TRIPS-II): a simple and practical neonatal illness severity score.

Authors:  Shoo K Lee; Khalid Aziz; Michael Dunn; Maxine Clarke; Lajos Kovacs; Cecil Ojah; Xiang Y Ye
Journal:  Am J Perinatol       Date:  2012-09-21       Impact factor: 1.862

2.  Neonatal acute kidney injury risk stratification score: STARZ study.

Authors:  Sanjay Wazir; Sidharth Kumar Sethi; Gopal Agarwal; Abhishek Tibrewal; Rohan Dhir; Naveen Bajaj; Naveen Parkash Gupta; Shishir Mirgunde; Jagdish Sahoo; Binesh Balachandran; Kamran Afzal; Anubha Shrivastava; Jyoti Bagla; Sushma Krishnegowda; Ananth Konapur; Kritika Soni; Abhyuday Rana; Timothy Bunchman; Rupesh Raina
Journal:  Pediatr Res       Date:  2021-05-19       Impact factor: 3.756

  2 in total
  2 in total

1.  STARZ Neonatal AKI Risk Stratification Cut-off Scores for Severe AKI and Need for Dialysis in Neonates.

Authors:  Sidharth Kumar Sethi; Rupesh Raina; Sanjay Wazir; Gopal Agrawal; Ananya Vadhera; Nikhil Nair; Kritika Soni; Abhishek Tibrewal
Journal:  Kidney Int Rep       Date:  2022-07-14

2.  Perspectives: Neonatal acute kidney injury (AKI) in low and middle income countries (LMIC).

Authors:  Mignon I McCulloch; Victoria M Adabayeri; Selasie Goka; Tholang S Khumalo; Nilesh Lala; Shannon Leahy; Nokukhanya Ngubane-Mwandla; Peter J Nourse; Beatrice I Nyann; Karen L Petersen; Cecil S Levy
Journal:  Front Pediatr       Date:  2022-08-31       Impact factor: 3.569

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.